[Cytostatic therapy of bronchial carcinoma].
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008727:Methotrexate / Q000627:therapeutic use; D010166:Palliative Care; D011344:Procarbazine / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D014228:Triaziquone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D014228:Triaziquone; D008727:Methotrexate
Die zytostatische Therapie des Bronchialkarzinoms.